Drug safety should be top-of-mind during COVID-19 developments - Dr. Andrew Rut in PharmaTimes

Drug safety should be top-of-mind during COVID-19 developments - Dr. Andrew Rut in PharmaTimes

News
08/06/20

Dr Andrew Rut discusses why monitoring drug safety will be key during COVID-19 developments, the lessons that can be learned from previous experience such as dengvaxia and the responsibility of the pharma community to build a body of scientific evidence through robust and reliable studies.

“If we fail to provide sufficient evidence to support the benefit-risk of treatments and vaccinations, then we expose global populations to three potential risks:

  • providing ineffective medicines to large populations
  • providing effective medicines that also cause significant harm when given to large populations
  • providing ineffective medicines that also cause significant harm to populations”

Read the full article in PharmaTimes here: Safety First: Drug safety should be top-of-mind during COVID-19 developments


Request More Information

To find out more or request a demo fill in the details below:


For more information contact chris.beverley@mymedsandme.com

Keep informed

For expert insight and updates from the MyMeds&Me team.

We respect your privacy and we will only use your email address for newsletters and company updates